Want to see GRDN full AI Analyst Report?
Top Page
Guardian Pharmacy Services, Inc. Class A
(NYSE:GRDN)
Select Model
Select Model
Rating:69Neutral
Price Target:
$42.00
▲(3.83% Upside)
Action:Reiterated
Date:08/07/26
GRDN scores highest on improving financial performance (strong growth, profitability rebound, and sharply reduced leverage). The score is tempered by premium valuation (high P/E, no dividend support) and only modest near-term technical momentum, while the earnings call and corporate updates were broadly positive but flagged ongoing IRA reimbursement headwinds and integration-related margin drag.
Positive Factors
Revenue and Profitability Improvement
Revenue has expanded strongly while the return to positive operating profit and net income shows improving operating leverage. This creates a stronger earnings base for the next several months, although modest net margins mean execution must continue.
Negative Factors
IRA Reimbursement Pressure
IRA pricing reductions are structurally pressuring reimbursement economics, with further tranches creating additional uncertainty. This can suppress reported growth, complicate planning, and require sustained operational mitigation to protect earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Profitability Improvement
Revenue has expanded strongly while the return to positive operating profit and net income shows improving operating leverage. This creates a stronger earnings base for the next several months, although modest net margins mean execution must continue.
Read all positive factors
Guardian Pharmacy Services, Inc. Class A (GRDN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.41B
Dividend YieldN/A
Average Volume (3M)348.83K
Price to Earnings (P/E)36.2
Beta (1Y)0.57
Revenue Growth10.31%
EPS GrowthN/A
CountryUS
Employees3,600
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)1.05
Shares Outstanding49,798,904
10 Day Avg. Volume450,542
30 Day Avg. Volume348,833
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)9.12
Price to Sales (P/S)1.30
P/FCF Ratio23.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$49.00Price Target Upside21.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.26
Revenue Forecast (FY)$1.41B
Guardian Pharmacy Services, Inc. Class A Business Overview & Revenue Model
Company Description
Guardian Pharmacy Services, Inc. operates as a pharmaceutical service provider, delivering an extensive array of tech-driven solutions. These services are specifically crafted to enhance the care of residents within long-term health care facilitie...
Guardian Pharmacy Services, Inc. Class A Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 17, 2026
Earnings Call Sentiment Positive
The call reflected a positive operational and financial trajectory: strong adjusted EBITDA growth (23% YTD; 19% Q/Q), improved gross profit (+18% YoY), raised full-year guidance, robust clinical impact and disciplined capital allocation with nearly $90M cash and active M&A/greenfield expansion. Offsetting these positives are clear reimbursement headwinds from IRA pricing reductions that materially depressed reported revenue (Q2 +2%) and are expected to cause low single-digit reported declines in H2, continued margin dilution from ramping acquisitions/greenfields (though improving), and some cost pressures (fuel). Management emphasized mitigation actions, internal succession and disciplined deployment of capital, leaving the outlook upgraded but with ongoing uncertainty tied to future IRA tranches and integration ramps.Positive Updates
Raised Full-Year Guidance
Company raised 2026 revenue guidance to $1.43B–$1.45B (from $1.40B–$1.42B) and adjusted EBITDA to $129M–$131M (from $123M–$127M), reflecting confidence based on year-to-date performance.
Negative Updates
IRA-Related Pricing Reductions Pressuring Reported Revenue
IRA-related pricing changes materially reduced reported revenue growth: reported revenue was only +2% YoY in Q2 but would have been low double-digits absent IRA. Management expects reported revenue to decline low single-digits YoY in the second half of 2026 due to continued IRA impact.
Read all updates
Q2-2026 Updates
Positive
Negative
Raised Full-Year Guidance
Company raised 2026 revenue guidance to $1.43B–$1.45B (from $1.40B–$1.42B) and adjusted EBITDA to $129M–$131M (from $123M–$127M), reflecting confidence based on year-to-date performance.
Read all positive updates
Company Guidance
Guardian raised full‑year 2026 guidance to revenue of $1.43–$1.45 billion (previously $1.40–$1.42B) and adjusted EBITDA of $129–$131 million (previously $123–$127M), reflecting strong YTD execution including H1 reported revenue +2% (would have been low‑double‑digit growth absent IRA pricing) and adjusted EBITDA growth of 23% in H1; Q2 results included revenue of $351.2M (+2% YoY), gross profit $80M (gross margin 22.8%), SG&A $56.5M (16.9% of revenue), adjusted EBITDA $29.7M (+19% YoY, 8.4% margin), net income $22.1M (includes an $8.5M settlement excluded from adj. EBITDA), residents served >210,000 (scripts up high single‑digits), cash ≈$90M (vs. ~$65M prior quarter), stock‑based comp ~$2.9M/quarter and an effective tax rate of 26%; management expects second‑half reported revenue to decline low‑single‑digits YoY due to IRA pricing (absent IRA underlying growth would be high‑single‑digits), adj. EBITDA margin roughly stable in Q3 with a seasonal Q4 pickup, the 2027 IRA tranche is ~40% of 2026’s, and guidance excludes any contribution from future acquisitions.Guardian Pharmacy Services, Inc. Class A Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.46B | 1.45B | 1.23B | 1.05B | 908.91M | 792.07M |
| Gross Profit | 316.58M | 282.04M | 244.37M | 208.31M | 185.87M | 161.26M |
| EBITDA | 114.00M | 96.42M | -43.43M | 58.81M | 68.15M | 46.49M |
| Net Income | 65.91M | 49.22M | -87.29M | 23.90M | 35.42M | 16.31M |
Balance Sheet | ||||||
| Total Assets | 443.58M | 412.66M | 320.81M | 271.17M | 256.11M | 235.85M |
| Cash, Cash Equivalents and Short-Term Investments | 89.81M | 65.62M | 4.66M | 752.00K | 607.00K | 15.01M |
| Total Debt | 35.24M | 37.14M | 37.33M | 69.15M | 62.98M | 55.04M |
| Total Liabilities | 185.94M | 194.73M | 170.83M | 211.31M | 180.18M | 182.53M |
| Stockholders Equity | 245.61M | 205.76M | 142.67M | 28.21M | 42.73M | 23.93M |
Cash Flow | ||||||
| Free Cash Flow | 79.78M | 80.71M | 41.59M | 56.26M | 31.75M | 49.22M |
| Operating Cash Flow | 98.86M | 100.29M | 57.96M | 70.82M | 48.52M | 58.50M |
| Investing Cash Flow | -22.73M | -32.26M | -30.41M | -13.44M | -17.90M | -13.15M |
| Financing Cash Flow | -5.13M | -7.07M | -23.64M | -57.23M | -45.03M | -36.79M |
Guardian Pharmacy Services, Inc. Class A Technical Analysis
Negative
40.45
Price Trends
40.73
Negative
39.17
Negative
35.19
Positive
Market Momentum
-0.55
Positive
42.92
Neutral
7.30
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRDN, the sentiment is Negative. The current price of 40.45 is above the 20-day moving average (MA) of 40.13, below the 50-day MA of 40.73, and above the 200-day MA of 35.19, indicating a neutral trend. The MACD of -0.55 indicates Positive momentum. The RSI at 42.92 is Neutral, neither overbought nor oversold. The STOCH value of 7.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GRDN.
Guardian Pharmacy Services, Inc. Class A Risk Analysis
Guardian Pharmacy Services, Inc. Class A disclosed 42 risk factors in its most recent earnings report. Guardian Pharmacy Services, Inc. Class A reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Guardian Pharmacy Services, Inc. Class A Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $100.26B | 22.91 | -194.39% | 0.39% | 8.84% | 48.98% | |
70 Outperform | $59.64B | 23.12 | 115.93% | 0.76% | 5.09% | 38.10% | |
69 Neutral | $2.41B | 36.19 | 30.80% | ― | 10.31% | ― | |
69 Neutral | $9.98B | 25.80 | 12.37% | ― | 6.49% | 10.41% | |
65 Neutral | $54.81B | 32.42 | -59.73% | 0.90% | 14.23% | 12.28% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
GRDN
Guardian Pharmacy Services, Inc. Class A
38.28
12.23
46.95%
COR
Cencora
317.10
15.71
5.21%
CAH
Cardinal Health
234.85
83.47
55.14%
HSIC
Henry Schein
89.29
20.65
30.08%
MCK
McKesson
853.71
153.62
21.94%
Guardian Pharmacy Services, Inc. Class A Corporate Events
Business Operations and StrategyExecutive/Board Changes
Guardian Pharmacy Announces Leadership Transition and Promotions
Positive
Jun 22, 2026
On June 22, 2026, Guardian Pharmacy Services, Inc. announced a planned leadership transition in its long-term care pharmacy business, highlighted by the retirement of Executive Vice President of Sales Operations Kendall Forbes, effective July 1, ...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Guardian Pharmacy Extends Revolving Credit Facility and Flexibility
Positive
May 28, 2026
On May 21, 2026, Guardian Pharmacy Services, Inc. and certain subsidiaries executed an eighth amendment to their existing loan and security agreement with Regions Bank and other lenders, updating the documentation to name the public company as bor...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.